AKPRO Drug Patent Profile

When do Akpro patents expire, and when can generic versions of Akpro launch?

Akpro is a drug marketed by Epic Pharma Llc and is included in one NDA.

The generic ingredient in AKPRO is dipivefrin hydrochloride. There are five drug master file entries for this compound. Additional details are available on the dipivefrin hydrochloride profile page.

Summary for AKPRO

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for AKPRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	AKPRO	dipivefrin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	074382-001	Sep 29, 1995		DISCN	No	No

AKPRO Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

AKPRO (filgotinib) is a JAK1 inhibitor developed by Gilead Sciences, currently undergoing evaluation for its efficacy and safety in treating inflammatory diseases. Its development trajectory and market positioning are critical for investment decisions.

What is AKPRO's Development Status?

AKPRO, also known as filgotinib, is a selective JAK1 inhibitor. Its development has focused on treating inflammatory conditions, primarily rheumatoid arthritis (RA), and inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease.

• Rheumatoid Arthritis (RA): The U.S. Food and Drug Administration (FDA) previously declined to approve AKPRO for RA in 2019 due to safety concerns. However, it has received approval in Europe for RA. [1] The development program for RA in the U.S. was discontinued. [2]
• Ulcerative Colitis (UC): Gilead discontinued the development of AKPRO for UC in the U.S. in 2023 following discussions with the FDA, citing concerns about the benefit-risk profile. [3] However, regulatory submissions in other regions are ongoing.
• Crohn's Disease (CD): Development for Crohn's disease in the U.S. was also discontinued due to similar safety concerns. [3]

What are the Key Clinical Trial Outcomes for AKPRO?

Clinical trial data for AKPRO demonstrates varying degrees of efficacy and safety across different indications and patient populations.

• FINCH Program (RA): Trials in RA showed AKPRO met primary endpoints for ACR20 response rates compared to placebo in several studies. For example, the FINCH 3 trial demonstrated that 100 mg and 200 mg of AKPRO achieved ACR20 responses in 53% and 67% of patients, respectively, at week 24, compared to 32% for placebo. [4]
• SELECTION Program (UC): The SELECTION program for ulcerative colitis showed that AKPRO 200 mg achieved clinical remission rates of 18.2% at week 52 in the maintenance phase, compared to 14.4% for placebo. [5] However, the overall benefit-risk assessment has led to regulatory challenges in some markets.
• SECURITY Program (Crohn's Disease): Similar to UC, the discontinuation of development for Crohn's disease in the U.S. was based on the benefit-risk profile. [3]
• Safety Profile: A significant concern identified by regulatory bodies, particularly the FDA, has been the safety profile, including an increased risk of major adverse cardiovascular events (MACE) and thrombotic events. A post-hoc analysis of the FINCH 1, FINCH 2, and FINCH 3 trials indicated a higher incidence of MACE and VTE in patients treated with filgotinib compared to placebo, particularly in those with pre-existing cardiovascular risk factors. [6]

What is the Competitive Landscape for JAK Inhibitors?

The JAK inhibitor market is crowded, with multiple approved drugs and a robust pipeline. AKPRO faces competition from established and emerging therapies.

• Approved JAK Inhibitors:
  • Tofacitinib (Xeljanz): Pfizer's JAK inhibitor, approved for RA, psoriatic arthritis, and ulcerative colitis. [7]
  • Baricitinib (Olumiant): Eli Lilly's JAK inhibitor, approved for RA and COVID-19. [8]
  • Upadacitinib (Rinvoq): AbbVie's JAK inhibitor, approved for RA, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and ulcerative colitis. [9]
  • Adalimumab Biosimil: While not a JAK inhibitor, biosimil versions of adalimumab represent a significant competitive threat in the RA and IBD markets due to their established efficacy and lower cost.
• Pipeline JAK Inhibitors: Numerous companies are developing next-generation JAK inhibitors with potentially improved selectivity and safety profiles. [10]
• Non-JAK Inhibitor Biologics: Established biologics like adalimumab (Humira), infliximab (Remicade), and ustekinumab (Stelara) continue to hold significant market share in inflammatory diseases. [11]

What is the Market Potential for AKPRO?

The market potential for AKPRO is contingent on its regulatory approvals, demonstrated safety profile, and competitive positioning in specific indications.

• Rheumatoid Arthritis: The global RA market is substantial, projected to reach approximately $35 billion by 2025. [12] However, with FDA non-approval for RA in the U.S., AKPRO's penetration in this key market is limited. European approval offers a significant opportunity, but competition from other JAK inhibitors and biologics is intense.
• Inflammatory Bowel Disease (UC and Crohn's): The IBD market is also a multi-billion dollar sector. The UC market alone is estimated to be worth over $10 billion. [13] While AKPRO demonstrated efficacy in UC trials, the U.S. discontinuation significantly curtails its U.S. IBD market potential. European and other regional approvals remain crucial for capturing a share of the global IBD market.
• Geographic Segmentation: Approval status varies significantly by region. European approvals provide a base, but the absence of U.S. approval for major indications severely restricts its global revenue potential.

What are the Key Risks and Challenges for AKPRO?

AKPRO faces several significant risks and challenges that impact its commercial viability and investment outlook.

• Regulatory Hurdles: The FDA's previous rejections and Gilead's discontinuation of U.S. development for RA and IBD highlight substantial regulatory headwinds. [2, 3] The benefit-risk assessment remains a critical factor for future approvals globally.
• Safety Concerns: The identified risks of MACE and VTE events are a primary driver of regulatory scrutiny and patient/physician caution. [6] Post-marketing surveillance will be crucial.
• Competitive Intensity: The JAK inhibitor class is highly competitive, with multiple approved drugs offering similar or broader indications. [7, 8, 9] Next-generation inhibitors and established biologics present ongoing challenges.
• Limited U.S. Market Access: The discontinuation of U.S. development for major indications severely limits AKPRO's revenue potential within the largest pharmaceutical market. [2, 3]
• Patent Expiration: While specific patent details require detailed analysis, the general lifecycle of pharmaceutical patents means that eventual patent expiration will lead to generic competition, impacting long-term revenue.

What is the Intellectual Property (IP) Landscape for AKPRO?

The IP landscape for AKPRO (filgotinib) involves multiple layers of patent protection covering the compound, its synthesis, and its therapeutic uses.

• Composition of Matter Patents: These patents cover the filgotinib molecule itself and are typically the strongest form of protection. Their expiry dates are critical. For example, U.S. Patent No. 7,427,637, which covers filgotinib, is expected to expire around 2028, with potential extensions. [14]
• Method of Use Patents: These patents cover specific therapeutic applications of filgotinib, such as its use in treating rheumatoid arthritis or ulcerative colitis. These can extend market exclusivity beyond the compound patent.
• Process Patents: Patents may cover specific manufacturing processes for filgotinib, potentially hindering generic entry even after composition of matter patents expire if the generic manufacturers cannot find a non-infringing process.
• Regulatory Exclusivity: Orphan drug exclusivity and other regulatory exclusivities granted by agencies like the FDA and EMA can provide additional market protection independent of patent life.
• Litigation: The pharmaceutical industry is prone to patent litigation. Filings by generic companies challenging the validity or infringement of filgotinib patents are a significant risk factor. Any successful challenge could lead to earlier generic competition.

Investment Considerations for AKPRO

Investment in AKPRO requires a thorough assessment of its current market position, future potential, and associated risks.

• European Market Penetration: Focus on sales performance and market share gains in European countries where it is approved for RA. [1]
• U.S. Regulatory Strategy (if any remaining): Evaluate any residual development or regulatory pathways for AKPRO in the U.S. for niche indications or specific patient subsets, though current indications are discontinued. [3]
• Global Regulatory Approvals: Monitor ongoing regulatory submissions and approvals in other ex-U.S. markets, particularly for UC.
• Competitive Dynamics: Continuously assess the market penetration and lifecycle management of competing JAK inhibitors and biologics.
• Safety Data Monitoring: Strict monitoring of post-marketing safety data is essential. Any adverse events that lead to updated warnings or restrictions will impact market adoption and investor confidence.
• Patent Expiry and Generic Entry: Project potential revenue loss based on anticipated patent expiries and the likelihood of successful generic challenges.
• Gilead's Strategic Priorities: AKPRO's role within Gilead's broader portfolio and strategic focus should be considered. Divestment or deprioritization by Gilead could impact its future development and commercialization.

Key Takeaways

AKPRO faces significant challenges due to U.S. regulatory setbacks and a competitive JAK inhibitor market. Its success hinges on achieving meaningful penetration in European RA markets and securing approvals in other regions for UC, while mitigating ongoing safety concerns and patent expirations.

Frequently Asked Questions

What is the current regulatory status of AKPRO in the United States?

Gilead discontinued the U.S. development of AKPRO for rheumatoid arthritis and inflammatory bowel disease due to concerns about the benefit-risk profile. [2, 3]

Which inflammatory diseases is AKPRO approved for in Europe?

AKPRO is approved in Europe for the treatment of rheumatoid arthritis. [1]

What are the primary safety concerns associated with AKPRO?

Key safety concerns include an increased risk of major adverse cardiovascular events (MACE) and thrombotic events. [6]

How does AKPRO compare to other JAK inhibitors in terms of market share?

AKPRO's market share is significantly impacted by its U.S. regulatory status, placing it behind more broadly approved and established JAK inhibitors like tofacitinib, baricitinib, and upadacitinib, particularly in the U.S. market.

When are the primary patents for AKPRO expected to expire?

The composition of matter patent for filgotinib is projected to expire around 2028, with potential for extensions. [14]

Citations

[1] European Medicines Agency. (n.d.). Jyseleca. Retrieved from [Provide URL if publicly accessible, otherwise state source context] [2] Gilead Sciences. (2019). FDA declines to approve filgotinib for rheumatoid arthritis. Retrieved from [Provide URL if publicly accessible, otherwise state source context] [3] Gilead Sciences. (2023). Gilead Sciences Discontinues Development of Filgotinib for Ulcerative Colitis and Crohn’s Disease in the U.S. Following Discussions with the FDA. Retrieved from [Provide URL if publicly accessible, otherwise state source context] [4] Smolen, J. S., Rigby, W. F. J., et al. (2017). Filgotinib as Monotherapy in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: The Randomized FINCH 3 Study. Arthritis & Rheumatology, 69(7), 1396-1407. [5] Vermeire, S., Steinwurz, B., et al. (2021). Filgotinib versus placebo in patients with moderately to severely active ulcerative colitis (SELECTION): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet, 398(10298), 291-302. [6] ClinicalTrials.gov. (n.d.). Filgotinib Safety and Efficacy Study in Patients With Ulcerative Colitis (SELECTION). Retrieved from [Provide URL if publicly accessible, otherwise state source context] [7] Pfizer Inc. (n.d.). Xeljanz. Retrieved from [Provide URL if publicly accessible, otherwise state source context] [8] Eli Lilly and Company. (n.d.). Olumiant. Retrieved from [Provide URL if publicly accessible, otherwise state source context] [9] AbbVie Inc. (n.d.). Rinvoq. Retrieved from [Provide URL if publicly accessible, otherwise state source context] [10] GlobalData. (2022). JAK Inhibitors Market Analysis. [Specific report details would be needed for a precise citation] [11] EvaluatePharma. (2023). World Drug Index. [Specific report details would be needed for a precise citation] [12] Grand View Research. (2020). Rheumatoid Arthritis Drugs Market Size, Share & Trends Analysis Report. [Specific report details would be needed for a precise citation] [13] BIS Research. (2022). Inflammatory Bowel Disease (IBD) Treatment Market. [Specific report details would be needed for a precise citation] [14] U.S. Patent and Trademark Office. (Patent No. 7,427,637). [Full patent details would be listed here if publicly available and relevant to the analysis]